Clinical value of the serum long noncoding RNA BC200 in the diagnosis and treatment of gastric cancer

Abstract

Objective To detect serum level of long noncoding RNA (lncRNA) BC200 in gastric cancer(GC) patients, and investigate its relationship with clinical features, and evaluate its diagnostic value for GC. Methods A case-control study was performed. From November 2014 to July 2015, serum levels of lncRNA BC200 were detected by real-time quantitative polymerase chain reaction in 124 patients with GC, 41 patients with atrophic gastritis and 59 normal controls who were hospitalized in Qilu Hospital of Shandong University. Meanwhile, serum carcinoembryonic antigen (CEA) and carbohydrate antigen 72-4 (CA72-4) were detected by electrochemical luminescence immunoassay. Serum levels of lncRNA BC200, before and 3, 7, 10, 30, 100 days after radical operation in another 31 patients with GC were determined. The sensitivity and specificity of serum lncRNA BC200, CEA and CA72-4 were analyzed by using of the receiver operating characteristic (ROC) curve. The comparison between two groups was performed with Mann-Whitney U test and the comparison among many groups was conducted with Kruskal-Wallis H test. Results Serum levels of lncRNA BC200 in GC patients with stage Ⅰ and Ⅱ[1.041(0.794, 1.462)]and stage Ⅲ and Ⅳ[1.290(0.978, 1.794)]were significantly higher than those in patients with precancerous lesion[0.969(0.699, 1.219)]and normal controls[0.801(0.556, 1.599)](H=54.68, P<0.000 1). Compared with pre-operation[1.120(0.859, 1.663)], the serum BC200 levels decreased significantly in 10 days[0.903(0.724, 1.182)](U=55.0, P<0.000 1), 30 days[0.759(0.671, 1.037)](U=299.0, P=0.026 1), and 100 days[0.478(0.378, 0.635)](U=41.0, P<0.000 1) after surgery. The area under the receiver operating characteristics curve(AUC) of serum lncRNA BC200 was 0.865 for GC diagnosis, which was significantly higher than that of serum CA72-4(AUC=0.699)or CEA(AUC=0.807). The AUC of combined detection of three tests was 0.934. Conclusion Serum lncRNA BC200 levels are significantly increased in GC patients, which may be used as a potential biomarker in GC diagnosis and monitoring.(Chin J Lab Med, 2017, 40: 138-142) Key words: Stomach neoplasms; RNA, long noncoding; Tumor markers, biological